NASDAQ$PCVX
Vaxcyte Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Vaxcyte announced financial results for the third quarter ended September 30, 2024, and provided a business update.
Vaxcyte reported positive topline data from Phase 1/2 study of VAX-31 and completed a follow-on equity offering, raising $1.4 billion in net proceeds. VAX-31 was selected to advance to Phase 3 program, with initiation expected by mid-2025. VAX-24 infant Phase 2 study topline data is expected by the end of the first quarter of 2025.
- Reported positive topline safety, tolerability and immunogenicity data from Phase 1/2 study of VAX-31 in adults aged 50 and older.
- VAX-31 selected to advance to Phase 3 program; initiation of Phase 3 pivotal, non-inferiority study expected by mid-2025.
- VAX-24 infant Phase 2 study topline data from primary immunization series expected by end of first quarter of 2025.
- Completed follow-on financing totaling $1.5 billion in gross proceeds.
Headline financials
Revenue & EPS history
Vaxcyte · Revenue · Quarterly
$0
Forward guidance
Vaxcyte is advancing the clinical development of its PCV programs with several anticipated key upcoming milestones.
Tailwinds
- Initiate a Phase 3 pivotal, non-inferiority study for VAX-31 by mid-2025 and announce topline data in 2026.
- Initiate remaining Phase 3 studies for VAX-31 in 2025 and 2026.
- Announce topline data from the primary three-dose immunization series of the Phase 2 study for VAX-24 by the end of the first quarter of 2025.
- Announce topline data from the booster dose for VAX-24 by the end of 2025.
- Initiate Phase 2 study for VAX-31 in the first quarter of 2025 subject to clearance of the IND application by year-end 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+0.6%
Avg return
Earnings day
+0.8%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+23.8%
Q2 2020
Best reaction
-21.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.7% | +1.0% | -13.3% | |
| Q3 2025 | -2.5% | +3.8% | +12.4% | |
| Q2 2025 | -9.1% | -9.1% | +0.1% | |
| Q1 2025 | +8.3% | +3.6% | +27.6% | |
| Q4 2024 | -0.9% | -9.1% | -12.5% | |
| Q3 2024 | -2.3% | +0.2% | -15.4% | |
| Q1 2024 | -2.9% | -2.7% | +5.1% | |
| Q4 2023 | -4.9% | -9.2% | -13.5% | |
| Q3 2023 | -1.0% | -5.1% | +10.8% | |
| Q2 2023 | -2.5% | -2.0% | +3.4% | |
| Q1 2023 | +3.7% | -3.7% | -0.3% | |
| Q4 2022 | -1.8% | +2.0% | -11.6% | |
| Q3 2022 | +4.2% | +3.3% | +0.6% | |
| Q2 2022 | +0.4% | +1.7% | +6.1% | |
| Q1 2022 | -11.4% | -3.0% | -14.8% | |
| Q4 2021 | +5.5% | +1.5% | +6.5% | |
| Q3 2021 | +3.4% | +4.7% | -12.7% | |
| Q2 2021 | +5.1% | +3.6% | +3.1% | |
| Q1 2021 | +13.5% | +17.0% | +40.5% | |
| Q4 2020 | -21.5% | -11.9% | -17.3% | |
| Q3 2020 | +3.9% | -0.2% | -15.3% | |
| Q2 2020 | +23.8% | +31.0% | +5.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro